Details for New Drug Application (NDA): 065137
✉ Email this page to a colleague
NDA 065137 describes CLARITHROMYCIN, which is a drug marketed by Sandoz, Sun Pharm Inds Ltd, Actavis Labs Fl Inc, Ani Pharms, Dr Reddys Labs Sa, Lupin Ltd, Nostrum Labs Inc, Ranbaxy, Sunshine, Ajanta Pharma Ltd, Alembic, Aurobindo, Chartwell, Hec Pharm, Hikma, Ivax Sub Teva Pharms, Norvium Bioscience, Strides Pharma, Teva, and Wockhardt, and is included in twenty-three NDAs. It is available from twenty-eight suppliers. Additional details are available on the CLARITHROMYCIN profile page.
The generic ingredient in CLARITHROMYCIN is clarithromycin. There are twenty-one drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the clarithromycin profile page.
The generic ingredient in CLARITHROMYCIN is clarithromycin. There are twenty-one drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the clarithromycin profile page.
Summary for 065137
| Tradename: | CLARITHROMYCIN |
| Applicant: | Ivax Sub Teva Pharms |
| Ingredient: | clarithromycin |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 065137
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 250MG | ||||
| Approval Date: | May 31, 2005 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | May 31, 2005 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
